Note: Ingredients listed on restricted chemical lists
EC/CAS
200-842-0/75-12-7
Name of the chemical
Formamide
Concentration
#3_T_CONCENTRATION
General Information
Version
3.1.0, issued
Revision date
2024-02-19
Product name
CyFlow BrettCount VIT F (Brett)
Emergency telephone
+49 (0)551 192 40
Icons in SDS
Company Information
company name
Sysmex Partec GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
info@sysmex-partec.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H351, H360FD, H373
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Hazard pictograms
GHS08
Signal word
Danger Hazardous component(s) to be indicated on label: FORMAMIDE
Hazard statements
H351 Suspected of causing cancer. H360FD May damage fertility. May damage the unborn child. H373 May cause damage to the blood through prolonged or repeated exposure if inhaled.
Precautionary statements
P201 Obtain special instructions before use. P260 Do not breathe mist/vapours/spray. P280 Wear protective gloves/protective clothing/eye protection/face protection. P308+P313 IF exposed or concerned: Get medical advice/attention.
Supplemental label elements
"Restricted to professional users"
2.3 Other hazards
PBT assessment No data available. vPvB assessment No data available.
2.1 Classification of the substance or mixture
Classification in accordance with Regulation (EC) No 1272/2008 (CLP) Carc. 2; H351 Repr. 1B; H360FD STOT RE 2; H373 Classification information This product is assessed and classified using the methods and criteria below referred to in Article 9 of Regulation (EC) n° 1272/2008: Physical hazards: determined through assessment data based on the methods or standards referred to in part 2 of Annex I to CLP Health hazards and environmental hazards: determined through toxicological and ecotoxicological assessment data based on the methods or standards referred to in Part 3, 4 and 5 of Annex I to CLP.